The US Meals and Drug Administration late Wednesday licensed booster doses of the Pfizer/BioNTech COVID-19 vaccine for individuals ages 65 and up. Additionally eligible for boosters shall be these ages 18 to 64 who’re at excessive danger of extreme COVID-19 or at excessive danger from frequent occupational or institutional exposures to SARS-CoV-2, corresponding to healthcare employees and academics.
The one booster dose ought to solely be given at the very least six months after the 2 preliminary doses. The authorization comes as an modification to an Emergency Use Authorization.
The FDA’s authorization largely follows the suggestions from a committee of impartial consultants that advises the company, referred to as the Vaccines and Associated Organic Merchandise Advisory Committee or VRBPAC. The committee met all day Friday to overview and deliberate over the information surrounding boosters. The assembly concluded with an 18-Zero vote in favor of recommending boosters for individuals 65 and up plus high-risk teams. However, previous to that, the committee voted 16-2 towards recommending boosters for everybody ages 16 and up, rejecting the Biden administration’s plans to rollout further doses to almost all vaccinated individuals.
Learn 7 remaining paragraphs | Feedback